Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 48 (1), 24-9

Distribution of Human Papillomavirus 52 and 58 Genotypes, and Their Expression of p16 and p53 in Cervical Neoplasia

Affiliations

Distribution of Human Papillomavirus 52 and 58 Genotypes, and Their Expression of p16 and p53 in Cervical Neoplasia

Tae Eun Kim et al. Korean J Pathol.

Abstract

Background: This study investigates the prevalence of human papillomavirus (HPV) 52 and 58 genotypes among women residing in Busan, and the expression of p16 and p53 proteins in cervical neoplasia with HPV 52 and 58 infections.

Methods: A total of three hundred fifteen cases were analyzed using the HPV DNA chip test for HPV genotypes, and of these, we retrospectively examined p16 and p53 expression in 62 cases of cervical tissues infected with HPV 52 and 58 using immunohistochemistry.

Results: HPV 52 and 58 genotypes were identified in 62 (54.9%) out of 113 high-risk, HPV-infected cases. Of the cases examined, there were 19 single HPV 52 infections (16.8%), 23 single HPV 58 infections (20.4%), 4 multiple HPV 52 infections (3.5%), and 16 multiple HPV-58 infections (14.2%). Immunoreactivity of p16 and p53 was observed in 41 (66.1%) and 23 (37.1%) of the 62 cases of cervical neoplasia infected with HPV 52 and 58 genotypes, respectively.

Conclusions: This study demonstrates a high prevalence of HPV 52 and 58 genotypes, in addition to HPV 16, among high-risk strains of cervical neoplasia in Korea. These findings suggest that development of more vaccines would be beneficial for the prevention of the various HPV genotypes.

Keywords: Cervical neoplasia; Cyclin-dependent kinase inhibitor p16; HPV 52; HPV 58; Tumor suppressor protein p53.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Distribution of high-risk human papillomavirus (HPV) infections.
Fig. 2
Fig. 2
Laser scanning results of human papillomavirus (HPV) 52 and 58 genotypes using HPV DNA chip. (A) Format of HPV DNA chip (M, position marker). (B) HPV negative. (C) HPV 52 positive. (D) HPV 58 positive.
Fig. 3
Fig. 3
Immunohistochemical studies for p16 (A, B) and p53 (C, D) in cervical intraepithelial neoplasia (CIN); positive nuclear and cytoplasmic reactions for p16 (A, CIN II; B, CIN III) and positive nuclear reactions for p53 (C, CIN II; D, CIN III).

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

References

    1. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11–22. - PubMed
    1. Shin HR, Jung KW, Won YJ, et al. National cancer incidence for the year 2002 in Korea. Cancer Res Treat. 2007;39:139–149. - PMC - PubMed
    1. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527. - PubMed
    1. Lee JH, Lee KH, Lee IH, et al. Clinical efficacy of HPV DNA chip test in human papillomavirus detection of uterine cervix. Korean J Obstet Gynecol. 2006;49:2128–2136.
    1. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73. - PMC - PubMed
Feedback